VIBERZI has blended opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist. The FDA's approval of VIBERZI is the first rung on the ladder to providing doctors with a new, evidence-based, treatment choice for their adult sufferers with IBS-D, said David Nicholson, Executive Vice President, Actavis Global Brands R&D generic viagra online . At Actavis, we are dedicated to providing new treatment plans, and the development of new brokers that help address the most bothersome symptoms of IBS-D. We have become pleased to be dealing with the FDA to progress this IBS-D treatment and we eagerly await DEA scheduling dedication later this season.
Actavis resolves patent litigation linked to generic edition of INTUNIV for treatment of ADHD Actavis, Inc.S. Sales of approximately $475 million for the 12 month period ending January 31, 2013 according to IMS Health.